C
Chimerix
Antiviral Drugs for DNA Viruses
About Chimerix
Chimerix, Inc. is a biopharmaceutical company focused on developing innovative antiviral therapies to address unmet medical needs in infectious diseases and oncology. The company primarily serves healthcare providers, hospitals, and patients who require advanced treatment options for life-threatening conditions. Operating in the biopharmaceutical market, Chimerix employs a research-driven business model, investing heavily in clinical trials and regulatory approvals to bring its products to market. Revenue is generated through the sale of approved therapies and potential partnerships or licensing agreements with other pharmaceutical companies. Key products include brincidofovir, an antiviral medication aimed at treating various viral infections. The company is also exploring treatments for acute myeloid leukemia and other cancers. Chimerix's strategic focus on high-need areas positions it as a critical player in the healthcare industry, aiming to improve patient outcomes through cutting-edge science.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2002
- Headquarters
- Durham, United States
- Listing
- IPO 2013
- Employees
- 100
- Open positions
- None listed
- Dealroom signal
- 63.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Mar 2025 | $935M | $935M | Jazz Pharmaceuticals | ↗ |
| GRANTOther financing | Nov 2022 | $2M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $212K | 0% | −$96M | -45506.1% |
| 2025 | $212K | 0% | −$96M | -45506.1% |
| 2024 | $212K | -34.6% | −$96M | -45506.1% |
| 2023 | $324K | -99% | −$93M | -28695.7% |
| 2022 | $34M | +1609.1% | −$290M | -857.5% |
| 2021 | $2M | -63.2% | −$7.6M | -385% |
| 2020 | $5.4M | — | −$45M | -828.7% |
Growth signals
Latest recorded traffic for Chimerix is 30 monthly website visits, down 97% over the last three months. Chimerix's team declined 20.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A1 investor entered at this stage
Asset Management Ventures
Series B and later8 investors entered at this stage
- FPFrazier Technology Partners
Sanderling Ventures
Canaan
Alta Partners
Frazier Healthcare Partners
New Leaf Venture Partners
Morningside
Pappas Capital
Other known investors1 additional known investor
Jazz Pharmaceuticals
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Chimerix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Chimerix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.